Perioperative Management of Apixaban

Preoperative Management

• The American College of Chest Physicians recommends discontinuing apixaban 2 days before high bleeding risk surgeries, which corresponds to approximately 4 half-lives expired and minimal (6%) residual anticoagulant effect at surgery, with examples including cardiac surgery, intracranial/spinal surgery, and major abdominal surgery 1, 2
• For low-to-moderate bleeding risk procedures, the American College of Chest Physicians suggests discontinuing apixaban 1 day before surgery, with examples including arthroscopy, colonoscopy biopsy, and abdominal hernia repair 1
• The American College of Chest Physicians also recommends considering longer interruption in patients with impaired renal function, as apixaban is less dependent on renal clearance (25%) than some other DOACs 2

Postoperative Management

• The American College of Chest Physicians recommends resuming apixaban 2-3 days after high bleeding risk surgery, with consideration of reduced dose (2.5 mg twice daily) for the first 2-3 days in patients at high risk for thromboembolism 2, 3
• For low bleeding risk surgery, the American College of Chest Physicians suggests resuming apixaban on the day after surgery (24 hours postoperatively) at the usual dose (5 mg twice daily), ensuring at least 24 hours have elapsed to allow sufficient time for wound hemostasis 2, 3
• The Anaesthesia journal recommends waiting at least 6 hours after the end of the invasive procedure before resuming therapy 4

Special Considerations

• The American College of Chest Physicians recommends considering postoperative factors that may affect drug absorption, such as bowel dysmotility after major abdominal surgery 5
• The Blood journal suggests that a patient's thromboembolic risk should drive whether there is a need for an aggressive perioperative antithrombotic strategy, while procedural bleeding risk determines the postprocedural management 6, 2
• The Blood journal also notes that apixaban has a half-life of 7-8 hours, with 25% renal clearance 2

Preoperative Management of Apixaban

Timing of Apixaban Discontinuation

• For patients with normal or mildly impaired renal function, the American College of Cardiology suggests discontinuing apixaban 3 days before high bleeding risk surgery, which corresponds to approximately 4 half-lives expired and minimal residual anticoagulant effect at surgery 7
• The European Society of Cardiology recommends discontinuing apixaban 4 days before high bleeding risk surgery for patients with moderate renal impairment (CrCl 30-50 mL/min) 8
• For low-to-moderate bleeding risk procedures, the American Heart Association suggests discontinuing apixaban 2 days before surgery in patients with normal or mildly impaired renal function 9
• The French Working Group on Perioperative Hemostasis recommends that for low bleeding risk procedures, the last intake of apixaban should be on the morning of the day before the planned invasive procedure 10

Bridging Anticoagulation

• The American College of Chest Physicians states that preoperative bridging by unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) is not recommended 10
• The European Society of Anaesthesiology suggests that there is no need to routinely measure the concentration of apixaban before the procedure 11

Postoperative Management

Resumption of Apixaban

• The American Heart Association recommends resuming apixaban 2-3 days after high bleeding risk surgery (48-72 hours postoperative) 7
• The European Society of Cardiology suggests waiting at least 6 hours after the end of the invasive procedure before resuming apixaban therapy 10

Perioperative Management of Apixaban

Preoperative Discontinuation

• For high bleeding risk surgeries, such as cardiac surgery, intracranial/spinal surgery, and major abdominal surgery, in patients with normal renal function, stop apixaban 3 days (72 hours) preoperatively, as recommended by the Anaesthesia guideline society 12
• The French Working Group recommends stopping apixaban the night before (last intake on the morning of the day before) for low bleeding risk procedures, with a strength of evidence based on expert opinion 12, 13

Bridging Anticoagulation

• The updated guidelines from the Anaesthesia guideline society specifically moved away from routine bridging based on evidence showing increased hemorrhagic risk without thrombotic risk reduction, with a high strength of evidence 12, 13
• Reserve bridging only for very high thrombotic risk patients, which should be determined by multidisciplinary discussion, as recommended by the Anaesthesia guideline society 13

Postoperative Resumption

• For low bleeding risk surgery, resume apixaban on the day after surgery (24 hours postoperatively) at the usual dose (5 mg twice daily), with a minimum waiting period of at least 6 hours after the end of the invasive procedure, as recommended by the Anaesthesia guideline society 12, 13
• For very low bleeding risk procedures, resumption can occur as early as 6 hours postoperatively, with a moderate strength of evidence 13

Special Considerations

• In the presence of an epidural catheter, do not resume therapeutic-dose apixaban, as recommended by the Anaesthesia guideline society 13
• Monitor renal function postoperatively if the procedure could affect kidney function, and adjust dosing accordingly, with a moderate strength of evidence 13

Common Pitfalls to Avoid

• Do not routinely measure apixaban concentrations before procedures when recommended interruption periods are followed, as recommended by the Anaesthesia guideline society 13
• Do not use bridging anticoagulation routinely, as it increases bleeding risk without reducing thrombotic events, with a high strength of evidence 13

Perioperative Management of Apixaban

Pre‑operative Interruption

• Low‑to‑moderate bleeding‑risk surgery – Stop apixaban 24 h (≈2–3 drug half‑lives) before the procedure, which leaves only minimal residual anticoagulant effect; examples include arthroscopy, colonoscopy with biopsy, and abdominal hernia repair. 14
• High‑bleeding‑risk surgery – Stop apixaban 48 h (≈4 half‑lives) before the operation, resulting in ≈6 % residual activity. 14
• Renal impairment – In patients with creatinine clearance 30–50 mL/min, extend the interruption by an additional day for high‑risk surgeries. Apixaban is cleared 25 % by the kidneys, so moderate renal dysfunction warrants this adjustment. 14, 15
• Severe renal dysfunction – The PAUSE trial excluded patients with CrCl < 25 mL/min, indicating that the above interruption strategy has not been validated in that population. 14

Heparin Bridging

• Routine bridging is not recommended for any apixaban‑treated patient, even those deemed at high thrombotic risk, because bridging offers no benefit and adds bleeding risk. The American College of Chest Physicians (ACCP) guideline cites high‑quality evidence from the PAUSE study showing a 0.16 % arterial thromboembolism rate and a 1.35 % major‑bleeding rate when no bridging was used. 14, 16
• Retrospective analyses of major DOAC trials confirm that 15–20 % of patients who received heparin bridging experienced comparable or higher major‑bleeding rates (2–5 %) without a reduction in thrombotic events. 14
• Guideline update – French peri‑operative anticoagulation recommendations (2020) explicitly advise against routine bridging because of the demonstrated increase in hemorrhagic complications without thrombotic benefit. 16
• Exception – Bridging may be considered only for extremely high‑risk situations (e.g., mechanical mitral valve, stroke within the past month) after multidisciplinary review. Even in atrial‑fibrillation patients with prior stroke, the short interruption (2–4 days total) makes bridging unnecessary. 14

Post‑operative Resumption

• Low‑to‑moderate risk procedures – Restart apixaban at the usual dose (5 mg twice daily) 24 h after surgery once adequate hemostasis is confirmed; for very low‑risk cases, resumption as early as 6 h is acceptable. 14, 15, 16
• High‑bleeding‑risk procedures – Restart apixaban 48–72 h after surgery. In patients with high thrombotic risk, a reduced dose (2.5 mg twice daily) may be used for the first 2–3 days before returning to the full dose. 14, 15
• Early thromboprophylaxis – When therapeutic apixaban must be delayed beyond 48 h, give low‑dose low‑molecular‑weight heparin for the first 2–3 days, then transition to full‑dose apixaban. 17

Monitoring & Pitfalls

• Laboratory testing – Routine coagulation assays (INR, aPTT) are insensitive to residual apixaban and should not guide peri‑operative management. DOAC‑specific anti‑factor Xa assays are more sensitive, but their routine use adds little value when standardized interruption protocols are followed. 14, 18
• Premature resumption – Restarting therapeutic anticoagulation before adequate hemostasis markedly increases major‑bleeding risk without lowering thrombotic events; early LMWH (<24 h) after major surgery has been associated with up to a 20 % major‑bleeding rate. 17
• Timing of safe restart – Minimum intervals before therapeutic apixaban can be safely resumed are ≥24 h for low‑risk and ≥48–72 h for high‑risk surgeries, reflecting the time needed for surgical site hemostasis. 14, 17

Strength of evidence: The recommendations are based on high‑quality prospective data from the PAUSE trial (large multicenter cohort) and corroborated by multiple retrospective analyses and updated national guidelines, providing Class I, Level A support for the interruption and non‑bridging strategies.